Dyne Therapeutics, Inc. (DYN)

NASDAQ: DYN · IEX Real-Time Price · USD
7.60 -0.45 (-5.59%)
Jan 25, 2022 4:00 PM EST - Market closed
Market Cap391.62M
Revenue (ttm)n/a
Net Income (ttm)-126.15M
Shares Out51.53M
EPS (ttm)-2.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,588,336
Open7.83
Previous Close8.05
Day's Range7.20 - 8.31
52-Week Range6.99 - 22.92
Betan/a
AnalystsBuy
Price Target34.75 (+357.2%)
Earnings Daten/a

About DYN

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.

IndustryIndependent Power and Renewable Electricity Producers
IPO DateSep 17, 2020
Employees88
Stock ExchangeNASDAQ
Ticker SymbolDYN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for DYN stock is "Buy." The 12-month stock price forecast is 34.75, which is an increase of 357.24% from the latest price.

Price Target
$34.75
(357.24% upside)
Analyst Consensus: Buy

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

New York, New York--(Newsfile Corp. - January 25, 2022) -  Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors...

8 hours ago - Newsfile Corp

Why Shares of Dyne Therapeutics Dropped 18.1% on Tuesday

A clinical hold regarding one of the company's therapies brought Dyne's shares to a 52-week low.

1 week ago - The Motley Fool

FDA Issues Clinical Hold On Dyne's IND For Duchenne Muscular Dystrophy Program

The FDA has placed a clinical hold on Dyne Therapeutics Inc's (NASDAQ: DYN) investigational New Drug (IND) application to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrop...

1 week ago - Benzinga

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

WALTHAM, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with ge...

1 week ago - GlobeNewsWire

Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with ge...

2 weeks ago - GlobeNewsWire

Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate

Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy.

1 month ago - Zacks Investment Research

Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscula...

- DYNE-251, Dyne's First DMD Program, is Being Developed for Patients with Mutations Amenable to Skipping Exon 51 -

1 month ago - GlobeNewsWire

Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

- Robust In Vivo Data Presented at Scientific Meetings Support Advancement of Dyne's Co-lead Candidates into the Clinic -

2 months ago - GlobeNewsWire

Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&...

- Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD During the Fourth Quarter of 2021 and for DYNE-101 in DM1 During the First Quarter of 2022 -

3 months ago - GlobeNewsWire

Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program

Dyne Therapeutics Inc (NASDAQ: DYN) has announced new data presented today during the 2021 Muscle Study Group Annual Scientific Meeting for its Duchenne muscular dystrophy (DMD) program. DMD is a rare d...

3 months ago - Benzinga

Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Ann...

- Dystrophin Restoration of 90% of Wild-Type Levels Observed in the Diaphragm and 78% in the Heart with ~80% Dystrophin-Positive Fibers After a Single Dose in mdx Mouse Model -

3 months ago - GlobeNewsWire

Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021

- “The Muscle to Move to the Clinic” Event Will Highlight Preclinical Data Supporting Advancement of Dyne's DM1 and DMD Programs Toward Clinical Trials and Anticipated Timelines, and Feature Leading Exp...

3 months ago - GlobeNewsWire

Dyne Therapeutics to Present at Chardan's Virtual 5th Annual Genetic Medicines Conference

WALTHAM, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with g...

3 months ago - GlobeNewsWire

Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robu...

- New In Vivo Data Also Show Sustained Knockdown of Toxic Human Nuclear DMPK RNA and Foci Reduction -

4 months ago - GlobeNewsWire

Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - New In Vivo Data from DM1 and DMD Programs to be Presented at Scientific Me...

5 months ago - GlobeNewsWire

Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD S...

- FORCE™ platform enables targeted muscle delivery with lead FSHD program candidate demonstrating potent suppression of DUX4 biomarkers in patient cell line -

7 months ago - GlobeNewsWire

Dyne Therapeutics Announces Chief Scientific Officer Transition

- Co-founder Romesh Subramanian, Ph.D., stepping down as chief scientific officer and will serve as an advisor after leading successful R&D and pipeline-building efforts -

7 months ago - GlobeNewsWire

Dyne Therapeutics' Myotonic Dystrophy Gene Therapy Shows Encouraging Action In Animal Studies

Dyne Therapeutics Inc (NASDAQ: DYN) has announced new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results demonstrating sustained knockdown of toxic human nuclear DMPK R...

8 months ago - Benzinga

Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of...

- Robust Reduction in DMPK RNA in Multiple Muscles at Four Weeks in Novel In Vivo Model Developed by Dyne; Additional In Vitro Data Support Advancement of Lead DM1 Candidate -

8 months ago - GlobeNewsWire

Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 -

8 months ago - GlobeNewsWire

New Preclinical Data from Dyne Therapeutics' Myotonic Dystrophy Type 1 Program to be Featured in Presentations During...

Company to host webcast including leading DM1 expert, Dr. Charles Thornton, following presentations on May 14, 2021 Company to host webcast including leading DM1 expert, Dr. Charles Thornton, following ...

8 months ago - GlobeNewsWire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

- Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4'21 and Q4'22 -

10 months ago - GlobeNewsWire

Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer

Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy in Neuromuscular Disease

10 months ago - GlobeNewsWire

Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs

Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease

11 months ago - GlobeNewsWire

Dyne Therapeutics Announces Pricing of $168 Million Public Offering

WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with ge...

1 year ago - GlobeNewsWire